|作者：||Han Tao, Luan Yuting, Xu Ying, Yang Xiaodan, Li Jing, Liu Ran, Li Qing, Zheng Zhendong|
1a Department of Oncology , Cancer Center of People's Liberation Army, General Hospital of Shenyang, Military Region , Shenyang , P.R. China.
2b Department of Clinical Pharmacy , Shenyang Pharmaceautical University , Shenyang , P.R. China.
3c Department of Radiotherapy , Cancer Center of People's Liberation Army, General Hospital of Shenyang Military Region , Shenyang , P.R. China.
4a Department of O
|刊名：||Cancer biology & therapy, 2017, Vol.18 (9), pp.635-639|
|关键词：||Apatinib; Liposarcoma; Paclitaxel; Pancreatic cancer; Prognosis;|
|原始语种摘要：||Pancreatic liposarcoma is a malignant tumor originated from the pancreas mesenchymal tissue and mostly presented in skin, subcutaneous, periosteum, and long bone on both sides. Both conventional chemotherapy and radiotherapy have limited efficacy and poor prognosis for advanced pancreatic liposarcoma. Here, we reported a case of advanced pancreatic liposarcoma and reviewed the literature specific for liposarcoma of the pancreas and discuss the emerging options of treatment. The patient was treated with apatinib and a cross-line rescue therapy combined with paclitaxel after progressive disease. The therapeutic effect of the combination regimen has been evaluated. Apatinib is an oral tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor... receptor-2 (VEGFR-2), which has dual effects of anti-angiogenesis and anti-tumor cell proliferation. To our knowledge, this is the first case to report the successful use of apatinib for advanced pancreatic liposarcoma.|